ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma

ACT001, which is derived from an ancient anti-inflammatory drug, has been shown to cross the blood-brain barrier in preclinical studies and has demonstrated anti-glioblastoma (GBM) activity in clinical trials. However, its pharmacological potential for anti-GBM immune response modulation remains unc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Theranostics
Main Authors: Tong, Luqing, Li, Jiabo, Li, Qiuying, Wang, Xuya, Medikonda, Ravi, Zhao, Tianna, Li, Tao, Ma, Haiwen, Yi, Li, Liu, Peidong, Xie, Yang, Choi, John, Yu, Shengping, Lin, Yu, Dong, Jun, Huang, Qiang, Jin, Xun, Lim, Michael, Yang, Xuejun
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2020
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7254983/
https://ncbi.nlm.nih.gov/pubmed/32483429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.41498
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados